CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

CK Life Sciences International (Holdings), Inc.

(HKEX:0775)

Select Model

Rating:47.2Neutral

Price Target:HKD 0.48▼(-1.43% Downside)

Action:reiterated

Date:08/21/26

The overall score is constrained mainly by recent financial deterioration in margins, profitability, cash generation, and returns amid meaningful leverage, while technicals indicate only modest short-term stabilization within a broader downtrend and the negative P/E undermines confidence in the current valuation.

Positive Factors

Diversified Life-Science BusinessExposure to both environmental solutions and health-related products gives CK Life Sciences more than one avenue for commercial activity. This diversified operating base can support resilience across end markets and provides opportunities to scale products and services in selected geographies over the medium term.

Negative Factors

Sharp Profitability DeteriorationThe sharp decline in gross margin and move into operating losses indicate that recent revenue is not converting into earnings effectively. If this weakness persists, it can reduce internally funded investment, pressure returns, and make future profitability more dependent on successful operational improvement.

CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 4.71B
Dividend Yield: ―
Average Volume (3M): 3.81M
Price to Earnings (P/E): -73.1
Beta (1Y): 0.69
Revenue Growth: 0.50%
EPS Growth: 76.90%
Country: Hong Kong
Employees: 1,920
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceut...

How the Company Makes Money

CK Life Sciences generates revenue primarily by selling and providing life-science-based products and services across its operating segments. Key revenue streams include (1) Environmental solutions: income from pest management offerings, typically ea...

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary

Score reflects historically stable revenue and prior profitability offset by a sharp 2025 deterioration in gross and net margins, a swing to negative EBIT, negative operating and free cash flow, and declining equity and ROE despite a still-sizeable asset base.

Income Statement

42Neutral

Balance Sheet

55Neutral

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.52B	5.41B	5.52B	5.32B	5.28B	5.40B
Gross Profit	739.27M	785.38M	1.69B	1.64B	1.63B	1.63B
EBITDA	76.28M	-49.42M	488.35M	624.75M	598.85M	574.15M
Net Income	-66.34M	-188.45M	-126.55M	17.25M	131.96M	162.80M
Balance Sheet
Total Assets	12.16B	11.84B	10.79B	11.25B	11.27B	11.73B
Cash, Cash Equivalents and Short-Term Investments	535.65M	603.07M	571.21M	676.16M	704.13M	902.47M
Total Debt	6.83B	6.62B	6.10B	5.93B	5.95B	6.21B
Total Liabilities	8.07B	7.99B	7.28B	7.06B	7.11B	7.23B
Stockholders Equity	3.95B	3.78B	3.51B	4.19B	4.16B	4.50B
Cash Flow
Free Cash Flow	-321.70M	-277.76M	157.00M	222.35M	146.69M	206.33M
Operating Cash Flow	-76.72M	-32.77M	353.53M	514.18M	363.66M	423.57M
Investing Cash Flow	-449.97M	-362.68M	-96.64M	-67.96M	-22.12M	-257.88M
Financing Cash Flow	262.71M	428.57M	-341.98M	-477.95M	-515.34M	-220.08M

CK Life Sciences International (Holdings), Inc. Technical Analysis

Technical Analysis SentimentNegative

Last Price0.49

Price Trends

50DMA0.55Negative

100DMA0.57Negative

200DMA0.67Negative

Market Momentum

MACD-0.02Positive

RSI39.78Neutral

STOCH5.56Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Negative. The current price of 0.49 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.55, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:0775 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2096	68Neutral	HKD 26.04B	14.11	16.54%	2.04%	27.24%	79.48%
HK:2696	65Neutral	HKD 26.75B	26.18	20.41%	―	32.63%	8.74%
HK:1177	61Neutral	HKD 85.83B	30.75	7.56%	2.49%	14.57%	-31.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:0775	47Neutral	HKD 4.71B	-73.13	-1.72%	―	0.50%	76.90%
HK:1877	41Neutral	HKD 30.07B	-69.15	-7.23%	―	35.82%	54.40%
HK:1672	30Underperform	HKD 5.15B	-7.05	-28.15%	―	-59.39%	-130.04%

* Healthcare Sector Average

Performance Comparison

HK:0775 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:0775	CK Life Sciences International (Holdings), Inc.	0.49	-0.40	-44.94%
HK:1177	Sino Biopharmaceutical	4.82	-2.13	-30.64%
HK:1672	Ascletis Pharma, Inc.	4.90	-4.91	-50.05%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.26	-11.44	-42.85%
HK:2096	Simcere Pharmaceutical Group Limited	10.14	-2.85	-21.96%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.06	-20.04	-29.00%

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Narrows Loss as Reorganised R&D Pipeline Advances in Oncology and Pain

Aug 11, 2026

CK Life Sciences reported an unaudited loss attributable to shareholders of HK$28.7 million for the first half of 2026, an 81% year-on-year reduction driven largely by a post-reorganisation change in accounting for R&D expenses. Following the sal...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

CK Life Sciences International (Holdings), Inc. AI Stock Analysis